Allosteric drugs: thinking outside the active-site box  by DeDecker, Brian S
Minireview R103
Recently, a class of small molecules that thermally
stabilize the tumor suppressor p53 was selected from a
small-molecule library. This, and other recent work,
demonstrates the feasibility of taking a lead from
nature and selecting new classes of drugs that function
by allosteric mechanisms.
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Conventional drug development has traditionally
focused on the active sites of proteins, and on identify-
ing molecules such as the HIV protease inhibitors that
bind to the active sites of proteins and block directly
interactions with the natural substrate. Besides this
direct mode of enzymatic regulation, nature makes
extensive use of allosteric (Greek: allos, other and stereos,
solid or space) interactions to regulate the activities of
proteins, especially in metabolic pathways and transcrip-
tional regulation. These types of interactions allow much
to be accomplished by a small molecule. For example,
the late Paul Sigler’s classic structural work on trp
repressor showed how the free energy of binding a small
molecule could pull the equilibrium from a state in
which the transcription factor was unable to bind DNA
to one in which it could [1] (Figure 1).
Allosteric mechanisms have several benefits. They allow a
particular reaction step to be regulated by the products of
other steps in the pathway or by other reaction pathways
altogether. They also allow highly specific regulation of an
enzyme. It is difficult, for example, to block directly a spe-
cific ATP-binding site by requiring the regulator to compete
with high concentrations of ATP for the targeted enzyme
and not bind the multiple related ATP-binding sites of other
proteins. Allosteric molecules bind to the protein outside the
highly conserved active site and can therefore have a wider
range of possible binding interactions.
Allosteric regulation is frequently used by biological
systems, as was predicted by Monod almost 40 years ago.
‘While possession of this almost universal key (allostery)
raises serious latent dangers for the experimenter, it is of
such value to living beings that natural selection must
have used it to the limit’ [2]. But it is rare that an attempt
is made to use the same principles in drug development.
Two recent studies on mutant p53 and nitric oxide syn-
thase are changing this trend. These studies demonstrate
the feasibility of taking a lead from nature and ‘designing’
new classes of allosteric drugs.
A small-molecule ‘Band-Aid’ for mutant p53
The tumor suppressor p53 responds to DNA damage
either by activating the transcription of regulatory genes
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Figure 1
Stereochemical basis of trp repressor
activation. Trp repressor in an inactive DNA
binding state on the left and an active
conformation bound to DNA and tryptophan
to the right. Tryptophan (blue) binds to and
stabilizes the DNA-binding conformation of
the trp repressor; with both helix–turn–helix
motifs (red) spread apart and aligned properly
for interaction with the DNA major groove.
Adapted from Zhang et al. [1].
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that arrest cell growth until the damage is repaired, or by
inducing apoptosis using both transcription dependent
and independent pathways. A single missense mutation to
the p53 allele can inactivate the protein and even cause a
dominant negative inactivation of wild-type protein
encoded by the unaffected allele. This inactivation results
in unregulated cell division leading to tumor growth;
indeed, over half of all human cancers can be attributed to
mutations in p53 [3].
The p53 protein consists of 393 amino acids that can be
divided into four major regions: a core DNA-binding
domain of 200 residues that folds independently into the
common immunoglobulin motif [4], an amino-terminal
transactivation domain, a tetramerization domain, and a
carboxy-terminal regulatory region. The core domain is
the most evolutionarily conserved of the domains, high-
lighting the essential role of DNA binding in p53 func-
tion. Substitution mutations in the core domain make up
98% of the transforming mutations in p53, 40% of which
are located in just six ‘hot spots’ [3].
Reverse protein engineering
To determine whether p53 mutants could, in principle, be
‘repaired’ by a small molecule, one could look at the results
of protein-engineering studies. Such studies can give hints
as to what is possible for a small-molecule interaction to
accomplish. For example, the allosteric mechanism of trp
repressor was confirmed by showing that the repressor
could also be activated by a point mutation [5]. When an
alanine that faces the tryptophan-binding pocket was
mutated to a bulkier valine, the larger sidechain was shown
to fill the binding-pocket cavity and activate the repressor
as tryptophan would when bound. The mutation therefore
mimicked the effect of a small molecule, and consequently
the reverse will at least sometimes be possible.
Protein-engineering studies on model systems have shown
that the energetic consequences of point mutations on
thermodynamic stability are generally cumulative [6,7].
For instance, the stability gain resulting from one point
mutation will be added to the stability gain of another in
the double mutant (assuming they are distant in the struc-
ture). Or, if the first mutation is destabilizing and the
second stabilizing, the overall free energy of unfolding
may be little changed. Stabilizing mutations can therefore
compensate for destabilizing mutations, such as those fre-
quently seen in p53 core domain. Two such general sup-
pressor mutations (Asn239→Τyr and Asn268→Asp) were
identified using a random mutagenesis screen for muta-
tions that restore transcription activity to a set of mutant
p53s [8]. Thermodynamic studies demonstrated that these
two particular suppressor mutations act as ‘global stability’
enhancers that indiscriminately stabilize the fold seen in
the wild-type protein and counteract the destabilizing
effects of tumorigenic mutations [8,9]. The small amount
of stabilizing energy expected from mutations of this kind
is similar to the levels that could reasonably be expected
from a small-molecule–protein interaction. These studies
suggested that allosteric stabilization of p53 mutants
seemed possible in principle.
The needle in the compound library haystack
To identify candidate stabilizers, Foster et al. [10] selected
small molecules from a random library using an assay that
took advantage of the mAb 1620 antibody, which recog-
nizes an epitope that is specific for the native conforma-
tion (Figure 2a). The core domain was immobilized in
microtiter wells and heated to 45°C, 3°C above the appar-
ent melting temperature of the isolated core domain [11],
to cause the protein to unfold irreversibly and lose the
conformationally sensitive mAb 1620 epitope after
30 minutes. A >100,000 member library of small molecules
was then screened for candidates that would prevent this
temperature-dependent loss of the mAb 1620 epitope and
effectively hyperstabilize the domain. Indeed a class of
relatively simple molecules was identified from the library
that, as a consequence of binding, stabilize the native con-
formation (Figure 2b). Just as certain suppressor mutations
both stabilize wild-type p53 and generally counteract
destabilizing point mutations, the small molecules that
were selected to stabilize wild-type p53 also stabilized a
random subset of mutant p53 core domains (Figure 2c).
The selected compounds had some structural features in
common: they all contain a polycyclic hydrophobic
moiety attached by a linker of a specific length to a posi-
tively charged amine group (Figure 2d). How the form of
these small molecules dictates their function remains to
be determined. As the compounds specifically stabilize
the native conformation they must bind to a surface of
the protein with a stereochemistry unique to the native
state. But the identification of this binding site and the
chemical nature of this stabilizing interaction awaits
structural studies.
Next, Foster et al. [10] tested the effectiveness of their
compounds in cells. As expected, the level of folded
mutant p53 increased; 4–6 hours after addition of com-
pound, a fivefold increase in mAb 1620 reactivity was
observed. The kinetics of this effect suggest that the
hyperstabilized mutant p53 was not rescued from the pool
of mutant p53 that had already become aggregated:
instead, newly synthesized p53 was stabilized and there-
fore prevented from entering the quagmire of aggregated
and chaperone-associated mutant p53. The stabilized
mutant p53 was also able to restore some level of tran-
scription of a luciferase reporter driven by a p53 promoter.
Finally, a correlation was shown between administering
the compounds and reducing tumor growth in mouse
models. Although these results are promising, the doses
required in mice are too high for the compound to be a
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practical therapy [12]. Could allostery-based approaches
go further along the same lines?
A double-barrelled gun for a magic bullet
The small molecules found by Foster et al. [10] were
selected to correct defects involved in thermal stability,
and would be expected to be most effective against muta-
tions that primarily affect protein folding, such as
the temperature-sensitive mutant Val143→Ala [13]
(Figure 3). This mutation is located in the core of the
protein and does not appreciably affect the DNA contact
residues: in this case, increasing the stability of the fold
restores sufficient DNA binding. Other p53 mutants,
however, such as Arg273→His (Figure 3) lack a crucial
DNA contact. Improving the stability of these mutant
proteins may not provide much functional benefit.
Recent quantitative thermodynamic studies show that
most p53 mutations affect both equilibria (protein folding
and DNA binding) to varying extents [11,14]. For
example, the aflatoxin-associated mutation Arg249→Ser
shows highly decreased affinity for DNA and its folding
equilibrium is significantly destabilized. Is it possible to
use an extension of the allosteric approach to stabilize the
DNA-bound state as well? Nature has accomplished this
feat in stabilizing the active state of trp repressor with
tryptophan. One way for a small molecule to stabilize the
protein–DNA complex is to make bridging interactions
across the protein–DNA interface; another possiblity is
that the small molecule could stabilize local unfolding in
the mutant protein, such as that caused by Arg249→Ser
in the DNA-binding loop L3 (B.S.D. and A.R. Fersht,
unpublished observations).
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Figure 2
Selection strategy for p53 stabilizers used by
Foster et al. [10]. (a) The wild-type p53 core
domain loses the mAb 1620 epitope and
gains mAb 240 reactivity upon heat
denaturation. (b) Immobilized p53 core
domain has no remaining mAb 1620 reactivity
after 30 min at 45°C. Addition of compounds
CP-31398 or CP-257042 stabilize the p53
fold, preserving mAb 1620 reactivity under
the heat-denaturing conditions in a
concentration-dependent fashion. (c) The two
compounds that were selected to stabilize
wild-type core domain also stabilize various
p53 point mutants. The stability of various p53
mutants ia compared between the proteins
alone (red) and in the presence of compound
(blue) incubated at 37°C for 30 min.
(d) Structures of two active compounds
(CP-31398 and CP-257042): both show a
polycyclic moiety attached to an amine.
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It may also be possible to find small molecules that relieve
the inactivation of specific DNA binding by the carboxy-
terminal regulatory region of p53 [15–17]. This region is
used by the cell to regulate p53 activity by phosphoryla-
tion and acetylation events targeted to this domain. Anti-
bodies that bind to this region, and peptides that mimic
and compete with it, effectively counter its negative regu-
latory effects. These antibodies and peptides are the most
effective against DNA-binding mutations such as
Arg273→His. Perhaps a small molecule equivalent to
these antibodies or peptides can be found.
Of course, there is one possible caveat in this approach,
altering the finely regulated DNA-binding equilibrium of
p53 in a general and unspecific way may have disastrous
consequences for healthy cells. As wild-type p53 core
domain is ~99% folded at body temperature, changing the
folding equilibrium would not be expected to affect
normal cell function significantly, and indeed the com-
pounds identified by Foster et al. [10] were not toxic. But
the situation for DNA binding is quite different, because
the DNA binding of p53 is normally downregulated in the
cell. One solution may be to tailor DNA stabilizers to the
specific mutation of interest. Once again, protein-engi-
neering studies suggest that this may be possible; suppres-
sor mutations that stabilize only the Arg249→Ser mutation
have been identified [8,9]. The disadvantage of such
mutation-specific molecules would be their limited applic-
ability. Mutations can, however, correlate with the type of
cancer or region of origin; for example, in certain areas of
Africa and Asia over 50% of hepatomas carry the
Arg249→Ser p53 mutation. In such regions a drug that
specifically targets the Arg249→Ser mutation would be
expected to have general success.
Allosteric modulation of protein–protein interactions in NO
synthase
A second recent example of the allosteric approach arose
serendipitously from a study that set out to identify
inhibitors that compete directly with the substrate in the
active site of an inducible nitric oxide synthase (iNOS)
[18]. Instead, this study identified a compound that
allosterically regulates the enzyme. The enzyme iNOS cat-
alyzes the NADPH-dependent oxidation of L-arginine to
citrulline and the important signaling molecule NO•. This
inducible enzyme’s role in signaling and its misfunction
has been implicated in inflammatory and autoimmune dis-
eases such as septic shock, hemorrhagic shock, rheumatoid
arthritis, osteoarthritis, inflammatory bowel disease and
multiple sclerosis. Needless to say, these observations have
made the specific inhibition of iNOS (but not the constitu-
tive NOS isoforms) a therapeutic goal.
McMillan et al. [18] selected inhibitors of iNOS from a
combinatorial library. The library was designed based on a
pyrimidineimidazole core, a structural class of compounds
known to bind the prosthetic heme group in the NOS
active site and competitively inhibit the binding of the
NOS substrate, L-arginine. The library was therefore
biased to search for compounds that blocked directly the
active site of the protein. The highly specific compounds
selected did in fact bind the active site, as shown by a co-
crystal structure, but they did not work in a straightfor-
ward competitive manner. Instead, they were found to
block the initial step of protein homodimerization that is
required to form active enzyme (Figure 4). In the
iNOS–compound complex, helix 7a was found to be disor-
dered, possibly because the compound displaced a residue
of the helix (Glu371) from the active site. In the iNOS
dimer structure, helix 7a buttresses helix 8 and residues
460–462 against the dimer interface, and the disruption of
helix 7a by compound binding may dismantle this binding
surface. Thus the fact that the compound-binding site
happens to also be the active site is in some sense coinci-
dental: the mechanism of action is the unexpected
allosteric disruption of protein–protein interactions
outside the active site.
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Figure 3
Ribbon diagram of the p53 core domain bound to a DNA half site
[4,21]. Sites of representative mutations are shown: Arg273→His
primarily reduces affinity for DNA, Val143→Ala mainly decreases the
stability of protein folding, and Arg249→Ser affects both equilibria.
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Prospects
Is selecting for allosteric molecules a generally plausible
strategy in drug-design efforts? Flexibility in protein–
protein interactions and protein–DNA interactions have
been well demonstrated [19,20]. If fluctuating states are
intrinsic to macromolecular interactions, then there is
hope for an approach aimed at using small-molecule
interactions to stabilize the state of interest, whether they
be hyperactive or inactive. Thinking outside the active-
site box requires a number of changes in experimental
design, such as using more varied small-molecule
libraries not biased for the active site and developing
assays that specifically search for allosteric interactions.
For instance, using enzyme assays that take reaction
kinetics into account would allow one to distinguish
between molecules that bind the active site (competitive
inhibitors) and ones that do not (noncompetitive and
uncompetitive inhibitors). Or, as in the iNOS sythase
example, it may just require keeping an eye open for
such unexpected activities. Nature has a way of devising
elegant solutions to design problems, and allosteric
control of protein function may be one solution worth
trying to emulate.
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Figure 4
(a) The iNOS active homodimer complex with the active site and part of
the dimer interface of one NOS molecule (green) shown bound to the
dimer interface of the other (blue). (b) The compound binds the arginine-
binding site (near the heme) and displaces helix 7a, causing the region
from the beginning of helix 7a to the middle half of helix 8 to be
disordered (inferred by lack of electron density) and possibly disrupts the
dimer interface by an allosteric mechanism. Helix 9 also shifts in position
between the two structures. Adapted from McMillan et al. [18].
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